What is the primary driver of Schering-Plough's recent financial performance improvement?

The primary driver is the strong performance of the cholesterol franchise, which includes the products VYTORIN and ZETIA, marketed through a joint venture with Merck & Co. These products have shown significant sales growth and contributed substantially to the company's equity income.

Are there any significant legal or regulatory issues that could impact the company's financial results?

Yes, Schering-Plough reached an agreement to settle the Massachusetts Investigation for $435 million to resolve issues related to sales, marketing, and clinical trial practices. The company also faces ongoing investigations and litigation related to pricing practices (AWP Investigations and Litigation) and other matters, which could potentially result in substantial fines or other remedies.

How is the company addressing its manufacturing operations and associated costs?

Schering-Plough announced plans to streamline its global supply chain by phasing out manufacturing operations in Manati, Puerto Rico, and implementing workforce reductions in Puerto Rico and New Jersey. These actions are expected to result in annual cost savings of approximately $100 million starting in 2007, though they also incurred special charges and accelerated depreciation in the current period.

What is the impact of the adoption of SFAS 123R on the company's financials?

Effective January 1, 2006, Schering-Plough adopted SFAS 123R, requiring the recognition of compensation expense for share-based payments based on their fair value. This led to the recognition of a cumulative effect of a change in accounting principle of $22 million in the first quarter of 2006 and affects the classification of tax benefits related to stock-based compensation from operating to financing activities.

MRK 10-Q Quarterly Report Q3 FY2006 — Revenue, Net Income, EPS

Summary

Schering-Plough Corporation's third quarter and year-to-date 2006 results demonstrate a significant turnaround, driven largely by the strong performance of its cholesterol franchise, VYTORIN and ZETIA, in partnership with Merck & Co. Net sales increased by 13% in the third quarter, reaching $2.6 billion, with year-to-date sales up 11% to $7.9 billion. Net income available to common shareholders saw a substantial jump to $287 million for the quarter and $875 million for the nine months, compared to $43 million and $78 million, respectively, in the prior year period. This improvement was partly offset by special charges related to manufacturing streamlining initiatives and a significant legal settlement for the Massachusetts Investigation. The company's financial health has improved considerably, with increased operating cash flow and a solid cash position. However, the financial performance remains heavily reliant on the cholesterol franchise, highlighting the need for continued success in this key market. Management is focused on investing in R&D and infrastructure to support future growth, while also navigating ongoing legal and regulatory challenges, including a substantial settlement for past sales and marketing practices.

Key Highlights

1Net sales for Q3 2006 increased by 13% to $2.6 billion, with nine-month sales up 11% to $7.9 billion, driven by key products like REMICADE, NASONEX, and TEMODAR.
2Net income available to common shareholders significantly improved to $287 million for Q3 2006 and $875 million for the nine months, a substantial increase from $43 million and $78 million in the prior year, respectively.
3The cholesterol joint venture with Merck & Co. (VYTORIN and ZETIA) continues to be a major revenue driver, with equity income from the venture increasing by 81% to $390 million in Q3 and 75% to $1.1 billion for the nine months.
4The company incurred $10 million in special charges for Q3 and $90 million for the nine months, primarily related to manufacturing streamlining initiatives involving facility closures and workforce reductions.
5A significant legal settlement was reached for $435 million to resolve the Massachusetts Investigation concerning sales, marketing, and clinical trial practices.
6Net cash provided by operating activities increased substantially to $1.5 billion for the nine months ended September 30, 2006, up from $546 million in the prior year period, indicating improved operational cash generation.
7The company adopted SFAS 123R (Share-Based Payment) effective January 1, 2006, impacting how stock-based compensation is recognized and impacting cash flow classifications for tax benefits.

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 2006

Summary

Key Highlights

Frequently Asked Questions